<b>Febuxostat is useful for cancer-associated hyperuricemia in patients with hematologic malignancies</b>

DOI Web Site

この論文をさがす

抄録

<p>Tumor lysis syndrome (TLS) causes hyperuricemia in patients with malignancies under chemotherapeutic treatment. Lowering serum uric acid (S-UA) levels is the most important. Febuxostat has been officially used for chemotherapy-associated hyperuricemia since May 2016 in Japan. Rasburicase and febuxostat reduce S-UA. Rasburicase is effective for high-risk TLS, and febuxostat for low-intermediate risk. Here, febuxostat was evaluated as a treatment for cancer-related hyperuricemia after becoming officially employed for TLS (June 2016 - November 2017). Sixty milligram was taken by mouth. The first chemotherapeutic treatment was started within a day after the first 60 mg dosing. The primary endpoint was S-UA normalization (≤ 7 mg/dL) on day 7 of chemotherapy. Twenty-four patients were evaluated (median: 70 years, range: 52-89 years, 14 males/10 females). The baseline S-UA was 7.2±2.7 mg/dL (mean±SD), and S-UA on the 7th day of chemotherapy was 2.5± 1.3 mg/dL (P<0.0001, by paired t-test). All patients met the primary endpoint. In addition, the baseline creatinine was 1.1±0.6 mg/dL (mean±SD), and the value on the 7th day of chemotherapy was 0.8±0.3 mg/dL (P=0.031, by paired t-test). Developing TLS was not observed. Severe adverse reactions were not noted. Thus, 60-mg febuxostat was effective against cancer-associated hyperuricemia.</p>

収録刊行物

  • 痛風と核酸代謝

    痛風と核酸代謝 42 (2), 157-164, 2018-12-20

    一般社団法人 日本痛風・核酸代謝学会

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ